← Back to Screener
BIOMERICA INC (BMRA)
Price$2.36
Value ScoreB
Growth ScoreD
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-9.34%
Price vs S&P 500 (4W)4.06%
VGM Score47.28
Market Capitalization$7.38M
All Metrics
Book Value / Share (Quarterly)$1.09
P/TBV (Annual)2.23x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-34.47%
Cash Flow / Share (Quarterly)$-1.05
Price vs S&P 500 (YTD)-16.18%
Gross Margin (TTM)4.32%
Net Profit Margin (TTM)-96.49%
EPS (TTM)$-1.59
10-Day Avg Trading Volume0.02M
EPS Excl Extra (TTM)$-1.59
Revenue Growth (5Y)-4.51%
EPS (Annual)$-2.16
ROI (Annual)-121.14%
Gross Margin (Annual)9.38%
Net Profit Margin (5Y Avg)-93.05%
Cash / Share (Quarterly)$0.44
Revenue Growth QoQ (YoY)-11.80%
ROA (Last FY)-83.65%
Revenue Growth TTM (YoY)-23.81%
EBITD / Share (TTM)$-1.96
ROE (5Y Avg)-81.57%
Operating Margin (TTM)-123.74%
Cash Flow / Share (Annual)$-1.52
P/B Ratio2.22x
P/B Ratio (Quarterly)1.85x
Net Income / Employee (Annual)$-93,800
EV / Revenue (TTM)1.40x
Net Interest Coverage (TTM)83.00x
ROA (TTM)-70.41%
EV / EBITDA (TTM)23.24x
EPS Incl Extra (Annual)$-2.16
Current Ratio (Annual)2.80x
Quick Ratio (Quarterly)1.46x
3-Month Avg Trading Volume0.02M
52-Week Price Return-24.44%
Revenue / Employee (TTM)$81,600
Tangible BV / Share (Quarterly)$1.02
P/S Ratio (Annual)1.39x
Asset Turnover (Annual)0.89x
52-Week High$4.60
Operating Margin (5Y Avg)-95.54%
EPS Excl Extra (Annual)$-2.16
CapEx CAGR (5Y)-20.97%
Tangible BV CAGR (5Y)-22.69%
26-Week Price Return6.59%
Quick Ratio (Annual)1.80x
13-Week Price Return16.47%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.64x
Enterprise Value$6.04M
Revenue / Share Growth (5Y)28.58%
Asset Turnover (TTM)0.73x
Book Value / Share Growth (5Y)5.90%
Revenue / Employee (Annual)$100,200
Inventory Turnover (Annual)2.49x
Pretax Margin (Annual)-93.62%
Cash / Share (Annual)$0.94
3-Month Return Std Dev51.35%
Gross Margin (5Y Avg)10.00%
Net Income / Employee (TTM)$-78,800
ROE (Last FY)-121.14%
Net Interest Coverage (Annual)-216.33x
EPS Basic Excl Extra (Annual)$-2.16
P/FCF (TTM)2.03x
Receivables Turnover (TTM)3.92x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.59
Receivables Turnover (Annual)6.33x
ROI (TTM)-98.14%
P/S Ratio (TTM)1.71x
Pretax Margin (5Y Avg)-92.62%
Revenue / Share (Annual)$2.31
Tangible BV / Share (Annual)$1.52
Price vs S&P 500 (52W)-52.65%
Year-to-Date Return-5.25%
5-Day Price Return-4.11%
EPS Normalized (Annual)$-2.16
ROA (5Y Avg)-60.11%
Net Profit Margin (Annual)-93.64%
Month-to-Date Return9.53%
Cash Flow / Share (TTM)$-0.41
EBITD / Share (Annual)$-2.20
Operating Margin (Annual)-96.72%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-81.57%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.59
P/TBV (Quarterly)1.99x
P/B Ratio (Annual)2.10x
Inventory Turnover (TTM)2.51x
Pretax Margin (TTM)-96.00%
Book Value / Share (Annual)$1.61
Price vs S&P 500 (13W)6.73%
Beta0.31x
P/FCF (Annual)6.53x
Revenue / Share (TTM)$1.44
ROE (TTM)-98.14%
52-Week Low$1.87
vGradeB
gGradeD
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q3 26-0.44est. —
Analyst Recommendations
Apr 2022
May 2022
Jun 2022
Jul 2022
4.29
4.29
4.29
4.29
Industry Peers — In Vitro Diagnostics(18)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BMRABIOMERICA INC | B | D | C | $2.36 |
| IDXXIdexx Laboratories Inc | D | B | C | $566.79 |
| LNTHLantheus Holdings, Inc | C | B | B | $97.13 |
| NNNNAnbio Biotechnology Class A Ordinary Shares | F | B | A | $30.17 |
| CLDXCelldex Therapeutics, Inc | F | F | B | $30.14 |
| NTLAIntellia Therapeutics, Inc | D | C | B | $13.73 |
| NEOGNeogen Corp | C | C | C | $8.92 |
| QDELQuidelOrtho Corporation Common Stock | B | C | D | $13.27 |
| ACHVAchieve Life Sciences, Inc. | F | F | B | $5.30 |
| MYGNMyriad Genetics Inc | C | C | D | $4.28 |
| TKNOAlpha Teknova, Inc. Common Stock | C | C | B | $5.37 |
About
Biomerica develops and markets medical diagnostic products for early detection and monitoring of chronic diseases, with a focus on gastrointestinal conditions, food intolerances, and diabetes. The company generates the majority of its revenue from Asia while maintaining a global presence across Europe, North America, the Middle East, and South America.